Star Health and Allied Insurance Company Analyst Review May 2026

This Star Health and Allied Insurance Company analyst review for May 2026 covers the key data investors need for STARHEALTH at its current price of Rs 490. Star Health and Allied Insurance Company (NSE: STARHEALTH) is India’s largest standalone health insurer with a market capitalisation of approximately Rs 29,000 crore, commanding over 30 percent individual health insurance market share. The analyst consensus target of Rs 600 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether STARHEALTH achieves that target through FY27.

Click Here – Get Free Investment Predictions

Star Health and Allied Insurance Company Company Snapshot May 2026

Star Health’s over 14,000 hospital empanelments are a structural moat. Claims ratio normalisation post the COVID spike and new product launches in senior citizen and critical illness categories are near-term catalysts. The table below summarises the key data referenced in this Star Health and Allied Insurance Company analyst review.

Parameter	Value
NSE Ticker	STARHEALTH
Sector	Health Insurance
CMP (May 2026)	Rs 490
52 Week High	Rs 620
52 Week Low	Rs 380
Market Cap	Rs 29,000 Crore
Trailing P/E	25.00x
Analyst Consensus Target	Rs 600
Bull Case Target	Rs 730
Bear Case Target	Rs 370

Analyst Insight in This Star Health and Allied Insurance Company Analyst Review

Associate Director Kunal Singla suggests watching Star Health and Allied Insurance Company closely in May 2026. At the current market price of Rs 490, Kunal Singla flags Health Insurance sector dynamics as a key driver for STARHEALTH’s near-term price action. He notes support in the Rs 388 to Rs 466 zone and flags any sustained close above Rs 519 as a positive signal worth tracking. Kunal Singla’s perspective on Star Health and Allied Insurance Company adds a layer of professional technical analysis to this Star Health and Allied Insurance Company analyst review and is not a buy recommendation.

Technical Analysis in This Star Health and Allied Insurance Company Analyst Review

At Rs 490, STARHEALTH is trading within its 52-week band of Rs 380 to Rs 620. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 388 to Rs 466 band while resistance is seen in the Rs 519 to Rs 545 zone. A sustained move above Rs 519 could open the path toward the analyst consensus of Rs 600.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 388 to Rs 466 – investors tracking this Star Health and Allied Insurance Company analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
• Resistance Zone: Rs 519 to Rs 545 – a sustained close above Rs 519 would be a positive breakout signal worth flagging.
• Medium-Term Target: The analyst consensus of Rs 600 represents the base-case upside for this Star Health and Allied Insurance Company analyst review.

Business Segment Analysis

Individual Health Insurance (Market Leader)

This is the primary revenue and margin driver for Star Health and Allied Insurance Company, directly supporting the earnings trajectory toward the consensus target of Rs 600.

Group Health Insurance for Corporates

This segment adds scale and diversification to Star Health and Allied Insurance Company’s business model and is a meaningful EPS contributor through FY27 and FY28.

Travel Insurance and Specialty Health Products

This represents the medium-term growth frontier for Star Health and Allied Insurance Company and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Star Health and Allied Insurance Company Analyst Review

At Rs 490, Star Health and Allied Insurance Company trades at a trailing P/E of 25.00x. This Star Health and Allied Insurance Company analyst review presents three scenarios: a bull case of Rs 730 on strong earnings delivery, a base case of Rs 600 at consensus, and a bear case of Rs 370 if macro headwinds persist. Q1 FY27 results will be the first key validation point.

Scenario	Target Price	Key Condition
Bull Case	Rs 730	Strong earnings and sector tailwinds
Base Case (Consensus)	Rs 600	Moderate growth, analyst consensus estimate
Bear Case	Rs 370	Earnings miss or macro headwinds

Trade Outlook for Star Health and Allied Insurance Company

Based on the technical and fundamental analysis in this Star Health and Allied Insurance Company analyst review, investors might watch STARHEALTH near the support zone of Rs 388 to Rs 466 for potential opportunities. A flag above Rs 519 could suggest improving momentum toward Rs 600. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Star Health and Allied Insurance Company in FY27

A well-rounded Star Health and Allied Insurance Company analyst review must assess downside risks. Key risks for Star Health and Allied Insurance Company include a macro slowdown affecting Health Insurance sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in STARHEALTH.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Star Health and Allied Insurance Company Analyst Review Verdict for 2026

This Star Health and Allied Insurance Company analyst review concludes that at Rs 490, STARHEALTH offers a defined risk-reward with a consensus target of Rs 600. The 52-week range of Rs 380 to Rs 620 provides context on the current entry point. Use this Star Health and Allied Insurance Company analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on STARHEALTH.

Frequently Asked Questions: Star Health and Allied Insurance Company Analyst Review 2026

What is the analyst target for Star Health and Allied Insurance Company in 2026?

The analyst consensus target is Rs 600, with a bull case of Rs 730 and a bear case of Rs 370. Monitor Q1 FY27 earnings for confirmation.

Is Star Health and Allied Insurance Company a good investment at Rs 490?

At Rs 490 with a P/E of 25.00x and a consensus target of Rs 600, this Star Health and Allied Insurance Company analyst review is constructive for medium to long-term investors in the Health Insurance sector. Always consult a SEBI-registered advisor before investing.

What is Star Health and Allied Insurance Company’s 52-week high and low?

The 52-week high is Rs 620 and the 52-week low is Rs 380. At Rs 490, STARHEALTH is positioned within this range as noted in this Star Health and Allied Insurance Company analyst review.

What are the key risks for Star Health and Allied Insurance Company?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Health Insurance sector.

Where can I get live data and analyst targets for Star Health and Allied Insurance Company?

Track Star Health and Allied Insurance Company’s live price and analyst targets on the Univest Screener alongside professional financial advice.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.